Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Nathalie Cook is an Accredited Practising Dietitian (APD) and Accredited Nutritionist (AN) and works in community health and private practice in Melbourne, Australia. She was diagnosed with myeloproliferative neoplam (MPN) in 2008 and has polythaemia vera (PV). Since her diagnosis, Nathalie has advocated for others with MPN as volunteer consumer representative with the Leukaemia Foundation, the MPN Alliance Australia (MPN AA) and the Australasian Leukaemia and Lymphoma Group (ALLG). From 2011 to 2018, Nathalie advocated to the pharmaceutical company Roche and the Australian government for Pegasys® (peginterferon alfa-2A) to be made available for prescription to MPN patients on Australia's government subsidised Pharmaceutical Benefits Scheme (PBS). Her advocacy efforts resulted in Australia’s first consumer-led PBS drug listing, and from August 1, 2018, Pegasys has been listed on the PBS for MPN.